AROVELLA THERAPEUTICS
Research AROVELLA THERAPEUTICS (E4NA) on Bullrun: market cap EUR 44.73M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerE4NA
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 44.73M
- Financial periodFY2025
- RevenueAUD 136.00K
- Revenue growth700.0%
- Net income-AUD 7.51M
- Free cash flow-AUD 7.34M
- Gross margin100.0%
Valuation Snapshot
latest market cap is EUR 44.73M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 136.00K | -AUD 7.51M | -AUD 7.34M | 100.0% | -0.01 | AUD 20.88M | n/a | AUD 20.08M |
| FY2024 | AUD 17.00K | -AUD 8.75M | -AUD 7.04M | 100.0% | -0.01 | AUD 12.71M | n/a | AUD 11.23M |
| FY2023 | AUD 405.90K | -AUD 10.18M | -AUD 6.40M | 49.9% | -0.01 | AUD 5.18M | n/a | AUD 3.78M |
| FY2022 | AUD 295.81K | -AUD 8.62M | -AUD 6.83M | 30.0% | -0.02 | AUD 6.07M | AUD 144.80K | AUD 7.62M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 44.73M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About AROVELLA THERAPEUTICS
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AROVELLA THERAPEUTICS's market cap?
AROVELLA THERAPEUTICS's market capitalization is EUR 44.73M.
What does AROVELLA THERAPEUTICS do?
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors.